ATS 2019 Virtual Final Program

8:05 Biology of Nicotine Addiction: Implication for Tobacco Treatment Strategies E.R. Neptune, MD, Baltimore, MD 8:30 Lung Cancer Screening: Challenges in Patient Selection and Implementation J. Iaccarino, MD, MSc, Boston, MA 8:55 Biomarkers in Lung Cancer: Are They Ready for Prime Time P.P. Massion, MD, Nashville, TN 9:20 Lung Cancer Staging 8th Edition: Special Considerations L.T. Tanoue, MD, New Haven, CT 9:45 Break 9:55 Minimally Invasive Surgery for NSCLC: VATS or RATS T.A. D’Amico, MD, Durham, NC 10:20 Alternative Treatment for Lung Cancer: Thermal Ablation R.D. Suh, MD, Los Angeles, CA 10:45 Alternative Treatment for Lung Cancer: SBRT A. Weiner, MD, Chapel Hill, NC 11:10 Tumor Board M.P. Rivera, MD, ATSF, Chapel Hill, NC 11:50 LUNCH 12:40 Diagnostic Bronchoscopic Tools Available to the Pulmonologist A.V. Gonzalez, MD, MSc, Montreal, Canada 1:05 Therapeutic Bronchoscopic Techniques Available to the Pulmonologist F. Maldonado, MD, Nashville, TN 1:30 The Expanding Role of Immunotherapy in the Treatment of Lung Cancer M.P. Rivera, MD, ATSF, Chapel Hill, NC 1:55 Treatment of Oligometastatic Disease: Pushing the Envelope to Improve Outcomes G.R. Simon, MD, Houston, TX 2:20 Break 2:30 Pulmonary and Cardiac Complications of Immunotherapy J.D. Possick, MD, New Haven, CT 2:55 Management of Malignant Pleural Effusions: ATS Guidelines D.H. Sterman, MD, ATSF, New York, NY 3:20 Tumor Board M.P. Rivera, MD, ATSF, Chapel Hill, NC This session and the International Conference are supported by an educational grant from AstraZeneca LP. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. ATS 2019 • Dallas, TX FRIDAY • MAY 17 11 FRIDAY